Question 1

Am I eligible for this trial based on my previous treatments and health status?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma clinical trial (NCT03470805). Contact the study team or your healthcare provider for specific answers.

Question 2

How does olaparib compare to other treatments I might consider after my current therapy?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma clinical trial (NCT03470805). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from olaparib?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma clinical trial (NCT03470805). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to visit the clinic for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma clinical trial (NCT03470805). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects or my cancer progresses while on this treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma clinical trial (NCT03470805). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any additional tests or procedures required for participation in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma clinical trial (NCT03470805). Contact the study team or your healthcare provider for specific answers.

What this study is about